Exome sequencing is a capture based method developed to identify variants in the coding region of genes which affect protein function. While exome capture methods using PCR, hybrid capture and molecular inversion probes exist, the most common and efficient strategies are in-solution capture methods. In-solution capture utilizes pools of oligonucleotides or probes bound to magnetic beads, whose sequence has been designed to hybridize to exon regions. After binding to genomic DNA, these probes are pulled down and washed, allowing exon regions to be selectively sequenced.
While there are approximately 180,000 exons in the human genome, constituting less than 2% of total sequence, the exome contains ~80-90% of known disease causing variants making it a cost-effective alternative to whole genome sequencing. When performing exome-seq, users should not only consider average on-target coverage but also the local coverage of particular sites of interest. When choosing between exome and whole genome sequencing (WGS), consider that exome sequencing has the advantage that oligonucleotides are designed to particular genomic regions where typical coverage with WGS is not enough for SNP calling. It is also more affordable enabling the analysis of more individuals and populations. With WGS, you can detect variants in regions not covered by exome capture allowing or the identification of structural and non-coding variants associated with disease.
麻豆原创 Analysis and Insights: Global Whole Exome Sequencing 麻豆原创
The global Whole Exome Sequencing market is projected to grow from US$ 332.6 million in 2024 to US$ 635.7 million by 2030, at a Compound Annual Growth Rate (CAGR) of 11.4% during the forecast period.
The major players in global Whole Exome Sequencing market include Illumina, Thermofisher, Roche, etc. The top 3 players occupy about 45% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Illumina TruSeq Exome and Roche Nimblegen SeqCap are main types, with a share about 55%. Mendelian Disease and Rare Syndrome Gene Discovery are the main application, which hold a share about 40%.
Report Covers:
This report presents an overview of global market for Whole Exome Sequencing market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Whole Exome Sequencing, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Whole Exome Sequencing, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Whole Exome Sequencing revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Whole Exome Sequencing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Whole Exome Sequencing revenue, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
Illumina
Thermo Fisher
Roche
Angilent
Eurofins
Sengenics
Ambry
Macrogen
BGI
Novo Gene
Segment by Type
Agilent HaloPlex
Agilent SureSelect
Agilent SureSelect QXT
Illumina TruSeq Exome
Roche Nimblegen SeqCap
MYcroarray MYbaits
Segment by Application
Correlation Research of Normal Human
Mendelian Disease and Rare Syndrome Gene Discovery
The Research of Complex Diseases
Mouse Exome Sequencing
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Whole Exome Sequencing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Whole Exome Sequencing companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Whole Exome Sequencing revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Whole Exome Sequencing 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Agilent HaloPlex
1.2.3 Agilent SureSelect
1.2.4 Agilent SureSelect QXT
1.2.5 Illumina TruSeq Exome
1.2.6 Roche Nimblegen SeqCap
1.2.7 MYcroarray MYbaits
1.3 麻豆原创 by Application
1.3.1 Global Whole Exome Sequencing 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Correlation Research of Normal Human
1.3.3 Mendelian Disease and Rare Syndrome Gene Discovery
1.3.4 The Research of Complex Diseases
1.3.5 Mouse Exome Sequencing
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Whole Exome Sequencing 麻豆原创 Perspective (2019-2030)
2.2 Global Whole Exome Sequencing Growth Trends by Region
2.2.1 Whole Exome Sequencing 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Whole Exome Sequencing Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Whole Exome Sequencing Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Whole Exome Sequencing 麻豆原创 Dynamics
2.3.1 Whole Exome Sequencing Industry Trends
2.3.2 Whole Exome Sequencing 麻豆原创 Drivers
2.3.3 Whole Exome Sequencing 麻豆原创 Challenges
2.3.4 Whole Exome Sequencing 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Whole Exome Sequencing by Players
3.1.1 Global Whole Exome Sequencing Revenue by Players (2019-2024)
3.1.2 Global Whole Exome Sequencing Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Whole Exome Sequencing 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Whole Exome Sequencing, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Whole Exome Sequencing 麻豆原创 Concentration Ratio
3.4.1 Global Whole Exome Sequencing 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Whole Exome Sequencing Revenue in 2023
3.5 Global Key Players of Whole Exome Sequencing Head office and Area Served
3.6 Global Key Players of Whole Exome Sequencing, Product and Application
3.7 Global Key Players of Whole Exome Sequencing, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Whole Exome Sequencing Breakdown Data by Type
4.1 Global Whole Exome Sequencing Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Whole Exome Sequencing Forecasted 麻豆原创 Size by Type (2025-2030)
5 Whole Exome Sequencing Breakdown Data by Application
5.1 Global Whole Exome Sequencing Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Whole Exome Sequencing Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Whole Exome Sequencing 麻豆原创 Size (2019-2030)
6.2 North America Whole Exome Sequencing 麻豆原创 Size by Type
6.2.1 North America Whole Exome Sequencing 麻豆原创 Size by Type (2019-2024)
6.2.2 North America Whole Exome Sequencing 麻豆原创 Size by Type (2025-2030)
6.2.3 North America Whole Exome Sequencing 麻豆原创 Share by Type (2019-2030)
6.3 North America Whole Exome Sequencing 麻豆原创 Size by Application
6.3.1 North America Whole Exome Sequencing 麻豆原创 Size by Application (2019-2024)
6.3.2 North America Whole Exome Sequencing 麻豆原创 Size by Application (2025-2030)
6.3.3 North America Whole Exome Sequencing 麻豆原创 Share by Application (2019-2030)
6.4 North America Whole Exome Sequencing 麻豆原创 Size by Country
6.4.1 North America Whole Exome Sequencing 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Whole Exome Sequencing 麻豆原创 Size by Country (2019-2024)
6.4.3 North America Whole Exome Sequencing 麻豆原创 Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Whole Exome Sequencing 麻豆原创 Size (2019-2030)
7.2 Europe Whole Exome Sequencing 麻豆原创 Size by Type
7.2.1 Europe Whole Exome Sequencing 麻豆原创 Size by Type (2019-2024)
7.2.2 Europe Whole Exome Sequencing 麻豆原创 Size by Type (2025-2030)
7.2.3 Europe Whole Exome Sequencing 麻豆原创 Share by Type (2019-2030)
7.3 Europe Whole Exome Sequencing 麻豆原创 Size by Application
7.3.1 Europe Whole Exome Sequencing 麻豆原创 Size by Application (2019-2024)
7.3.2 Europe Whole Exome Sequencing 麻豆原创 Size by Application (2025-2030)
7.3.3 Europe Whole Exome Sequencing 麻豆原创 Share by Application (2019-2030)
7.4 Europe Whole Exome Sequencing 麻豆原创 Size by Country
7.4.1 Europe Whole Exome Sequencing 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Whole Exome Sequencing 麻豆原创 Size by Country (2019-2024)
7.4.3 Europe Whole Exome Sequencing 麻豆原创 Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Whole Exome Sequencing 麻豆原创 Size (2019-2030)
8.2 China Whole Exome Sequencing 麻豆原创 Size by Type
8.2.1 China Whole Exome Sequencing 麻豆原创 Size by Type (2019-2024)
8.2.2 China Whole Exome Sequencing 麻豆原创 Size by Type (2025-2030)
8.2.3 China Whole Exome Sequencing 麻豆原创 Share by Type (2019-2030)
8.3 China Whole Exome Sequencing 麻豆原创 Size by Application
8.3.1 China Whole Exome Sequencing 麻豆原创 Size by Application (2019-2024)
8.3.2 China Whole Exome Sequencing 麻豆原创 Size by Application (2025-2030)
8.3.3 China Whole Exome Sequencing 麻豆原创 Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Whole Exome Sequencing 麻豆原创 Size (2019-2030)
9.2 Asia Whole Exome Sequencing 麻豆原创 Size by Type
9.2.1 Asia Whole Exome Sequencing 麻豆原创 Size by Type (2019-2024)
9.2.2 Asia Whole Exome Sequencing 麻豆原创 Size by Type (2025-2030)
9.2.3 Asia Whole Exome Sequencing 麻豆原创 Share by Type (2019-2030)
9.3 Asia Whole Exome Sequencing 麻豆原创 Size by Application
9.3.1 Asia Whole Exome Sequencing 麻豆原创 Size by Application (2019-2024)
9.3.2 Asia Whole Exome Sequencing 麻豆原创 Size by Application (2025-2030)
9.3.3 Asia Whole Exome Sequencing 麻豆原创 Share by Application (2019-2030)
9.4 Asia Whole Exome Sequencing 麻豆原创 Size by Region
9.4.1 Asia Whole Exome Sequencing 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Whole Exome Sequencing 麻豆原创 Size by Region (2019-2024)
9.4.3 Asia Whole Exome Sequencing 麻豆原创 Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Whole Exome Sequencing 麻豆原创 Size (2019-2030)
10.2 Middle East, Africa, and Latin America Whole Exome Sequencing 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Whole Exome Sequencing 麻豆原创 Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Whole Exome Sequencing 麻豆原创 Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Whole Exome Sequencing 麻豆原创 Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Whole Exome Sequencing 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Whole Exome Sequencing 麻豆原创 Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Whole Exome Sequencing 麻豆原创 Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Whole Exome Sequencing 麻豆原创 Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Whole Exome Sequencing 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Whole Exome Sequencing 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Whole Exome Sequencing 麻豆原创 Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Whole Exome Sequencing 麻豆原创 Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Illumina
11.1.1 Illumina Company Details
11.1.2 Illumina Business Overview
11.1.3 Illumina Whole Exome Sequencing Introduction
11.1.4 Illumina Revenue in Whole Exome Sequencing Business (2019-2024)
11.1.5 Illumina Recent Developments
11.2 Thermo Fisher
11.2.1 Thermo Fisher Company Details
11.2.2 Thermo Fisher Business Overview
11.2.3 Thermo Fisher Whole Exome Sequencing Introduction
11.2.4 Thermo Fisher Revenue in Whole Exome Sequencing Business (2019-2024)
11.2.5 Thermo Fisher Recent Developments
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Whole Exome Sequencing Introduction
11.3.4 Roche Revenue in Whole Exome Sequencing Business (2019-2024)
11.3.5 Roche Recent Developments
11.4 Angilent
11.4.1 Angilent Company Details
11.4.2 Angilent Business Overview
11.4.3 Angilent Whole Exome Sequencing Introduction
11.4.4 Angilent Revenue in Whole Exome Sequencing Business (2019-2024)
11.4.5 Angilent Recent Developments
11.5 Eurofins
11.5.1 Eurofins Company Details
11.5.2 Eurofins Business Overview
11.5.3 Eurofins Whole Exome Sequencing Introduction
11.5.4 Eurofins Revenue in Whole Exome Sequencing Business (2019-2024)
11.5.5 Eurofins Recent Developments
11.6 Sengenics
11.6.1 Sengenics Company Details
11.6.2 Sengenics Business Overview
11.6.3 Sengenics Whole Exome Sequencing Introduction
11.6.4 Sengenics Revenue in Whole Exome Sequencing Business (2019-2024)
11.6.5 Sengenics Recent Developments
11.7 Ambry
11.7.1 Ambry Company Details
11.7.2 Ambry Business Overview
11.7.3 Ambry Whole Exome Sequencing Introduction
11.7.4 Ambry Revenue in Whole Exome Sequencing Business (2019-2024)
11.7.5 Ambry Recent Developments
11.8 Macrogen
11.8.1 Macrogen Company Details
11.8.2 Macrogen Business Overview
11.8.3 Macrogen Whole Exome Sequencing Introduction
11.8.4 Macrogen Revenue in Whole Exome Sequencing Business (2019-2024)
11.8.5 Macrogen Recent Developments
11.9 BGI
11.9.1 BGI Company Details
11.9.2 BGI Business Overview
11.9.3 BGI Whole Exome Sequencing Introduction
11.9.4 BGI Revenue in Whole Exome Sequencing Business (2019-2024)
11.9.5 BGI Recent Developments
11.10 Novo Gene
11.10.1 Novo Gene Company Details
11.10.2 Novo Gene Business Overview
11.10.3 Novo Gene Whole Exome Sequencing Introduction
11.10.4 Novo Gene Revenue in Whole Exome Sequencing Business (2019-2024)
11.10.5 Novo Gene Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Illumina
Thermo Fisher
Roche
Angilent
Eurofins
Sengenics
Ambry
Macrogen
BGI
Novo Gene
听
听
*If Applicable.